Comparison between Molbio Diagnostics IPO and OnEMI Technology IPO.
Molbio Diagnostics IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while OnEMI Technology IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Molbio Diagnostics IPO is up to ₹0.00 Cr whereas the issue size of the OnEMI Technology IPO is up to ₹0.00 Cr. The final issue price of Molbio Diagnostics IPO is and of OnEMI Technology IPO is .
| Molbio Diagnostics IPO | OnEMI Technology IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹200.00 Cr | up to ₹1,000.00 Cr |
| OFS Issue Size | 1,25,56,000 shares | 88,79,575 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Molbio Diagnostics IPO opens on , while OnEMI Technology IPO opens on . The closing date of Molbio Diagnostics IPO and OnEMI Technology IPO is , and , respectively.
Molbio Diagnostics IPO P/E ratio is , as compared to OnEMI Technology IPO P/E ratio of .
| Molbio Diagnostics IPO | OnEMI Technology IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Molbio Diagnostics Ltd.'s revenue increased by 22% and profit after tax (PAT) rose by 66% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)OnEMI Technology Solutions Ltd.'s revenue decreased by 20% and profit after tax (PAT) dropped by 19% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 46.65 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 16.20% | 17.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 20.98% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹12.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 15.23% | 17.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Molbio Diagnostics IPO Retail Individual Investors (RII) are offered 0 shares while in OnEMI Technology IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Molbio Diagnostics IPO and 0 shares in OnEMI Technology IPO.
| Molbio Diagnostics IPO | OnEMI Technology IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Molbio Diagnostics IPO subscribed in total, whereas OnEMI Technology IPO subscribed .
